(4) The mediating role of CD3 on naive CD8+ T cells and CD4+ T cells suggests that a combination of specific PAU with CD3 agonist-related immunotherapy may be a promising therapeutic option for liver cancer treatment, and this deserves future study. Here, CD8A is linked to liver cancer.